Application of musculoskeletal ultrasound in ankylosing spondylitis with peripheral osteophytes

doi:10.3969/j.issn.1004-583X.2024.09.003

Abstract

Abstract:

Objective To investigate the application of musculoskeletal ultrasound in ankylosing spondylitis (AS) patients with peripheral osteophytes. Methods Peripheral joint ultrasound examination was performed in 80 patients with AS. According to the detection of osteophytes, the patients were divided into the observation group (42 cases with osteophytes) and the control group (38 cases without osteophytes). The clinical characteristics, laboratory indexes, dual-energy bone mineral density (BMD) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score were compared. The t-test and Sperman's rank correlation were used for statistical analyses. Results The highest incidence of osteophytes of finger joints (33.3%) was detected in the observation group. The C-reactive protein (CRP), BASDAI score and course of disease in the observation group were significantly higher than those of the control group, and the BMD was significantly lower (P<0.05). In the observation group, the erythrocyte sedimentation rate (ESR), CRP and course of disease in the smoking subgroup were significantly higher than those of the non-smoking subgroup (P<0.05). CRP was positively correlated with ESR, BASDAI score and smoking index. Conclusion Inflammatory response in patients with AS is related to osteophyte formation. Musculoskeletal ultrasound is used to detect osteophytes, which is helpful to disease assessment.

Key words: spondylitis, ankylosing, osteophyte, musculoskeletal ultrasonography

CLC Number:

R593.23

Xie Jianli, Wang Junxiang, Chen Haiying. Application of musculoskeletal ultrasound in ankylosing spondylitis with peripheral osteophytes[J]. Clinical Focus, 2024, 39(9): 787-791.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.09.003

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I9/787

Figures/Tables 4

Tab.1 Clinical data between the observation group and the control group

组别	例数	ESR(mm/h)	CRP(mg/L)	BMD	BASDAI评分(分)	骶髂关节分级(级)	病程(年)
观察组	42	5.10±1.43	73.95±25.69	-2.39±0.19	61.70±31.61	3.50±0.50	18.13±6.17
对照组	38	4.45±1.31	29.76±17.16	0.89±0.35	33.27±24.74	3.00±0.00	10.52±3.15
$t$ 值		1.073	2.542	-9.235	2.312	1.100	2.123
P值		0.292	0.041	<0.01	0.032	0.252	0.043

Tab.1 Clinical data between the observation group and the control group

组别	例数	ESR(mm/h)	CRP(mg/L)	BMD	BASDAI评分(分)	骶髂关节分级(级)	病程(年)
观察组	42	5.10±1.43	73.95±25.69	-2.39±0.19	61.70±31.61	3.50±0.50	18.13±6.17
对照组	38	4.45±1.31	29.76±17.16	0.89±0.35	33.27±24.74	3.00±0.00	10.52±3.15
$t$ 值		1.073	2.542	-9.235	2.312	1.100	2.123
P值		0.292	0.041	<0.01	0.032	0.252	0.043

Tab.2 Clinical data between the smoking group and nonsmoking group

组别	例数	ESR(mm/h)	CRP(mg/L)	BMD	BASDAI(分)	病程(年)	骶髂关节分级(级)
吸烟组	15	47.55±35.44	88.54±68.15	-0.68±1.67	5.05±1.54	14.09±12.72	3.27±0.47
非吸烟组	27	25.11±28.35	36.50±22.13	-0.66±2.09	4.55±1.20	9.20±7.45	3.20±0.42
$t$ 值		2.071	2.126	0.023	0.921	1.080	0.372
P值		0.041	0.033	0.980	0.372	0.030	0.716

Tab.2 Clinical data between the smoking group and nonsmoking group

组别	例数	ESR(mm/h)	CRP(mg/L)	BMD	BASDAI(分)	病程(年)	骶髂关节分级(级)
吸烟组	15	47.55±35.44	88.54±68.15	-0.68±1.67	5.05±1.54	14.09±12.72	3.27±0.47
非吸烟组	27	25.11±28.35	36.50±22.13	-0.66±2.09	4.55±1.20	9.20±7.45	3.20±0.42
$t$ 值		2.071	2.126	0.023	0.921	1.080	0.372
P值		0.041	0.033	0.980	0.372	0.030	0.716

Tab.3 Correlation analysis of the clinical data in the observation group

项目	骶髂关节分级	病程	ESR	CRP	BMD	BASDAI评分	SI
骶髂关节分级	1	0.74^#	0.43^*	0.05	-0.51^*	0.22	0.08
病程	0.74^#	1	0.49^*	0.17	-0.78^#	0.22	0.23
ESR	0.43^*	0.49^*	1	0.69^#	-0.40	0.84^#	0.02
CRP	0.05	0.17	0.69^#	1	-0.21	0.82^#	0.43*
BMD	-0.51^*	-0.78^#	-0.40	-0.21	1	-0.19	0.00
BASDAI	0.22	0.22	0.84^#	0.82^#	-0.19	1	-0.20
SI	0.05	0.23	0.02	0.43*	0.00	-0.20	1

Fig.1 New bone formation process hypothesis

References 28

[1]	Aniruddha V, Paul B. New developments in our understanding of ankylosing spondylitis pathogenesis[J]. Immunology, 2020, 161(2): 94-102.
[2]	Hwang MC, Lee M, Gensler LS, et al. Repeated spinal mobility measures and their association with radiographic damage in ankylosing spondylitis[J]. ACR Open Rheumatol, 2021, 3(6): 413-421.
[3]	Viitanen JV, Heikkila S, Kokko ML, et al. Clinical assessmentof spinal mobility measurements in ankylosing spondylitis: A compact set for follow-up and trials[J]? Clinical Rheumatol, 2000, 19(2):131-137.
[4]	金璐. CT诊断强直性脊柱炎骶髂关节病变及评价关节损伤程度的效果研究[J]. 四川医学, 2020, 41(1):92-95.
[5]	黄烽, 朱剑, 王玉华, 等. 强直性脊柱炎诊疗规范[J]. 中华内科杂志, 2022, 61(8):893-900.
[6]	Machado P, Landewé R, Braun J, et al. Both structural damage and inflammation of the spine con-tribute to impairment of spinal mobility in patients with ankylosing spondylitis[J]. Ann Rheum Dis, 2010, 69(8):1465-1470. doi: 10.1136/ard.2009.124206 pmid: 20498215
[7]	Rudwaleit M, van der Heijde D, Landewé R, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): Validation and final selection[J]. Ann Rheum Dis, 2009, 68(6):777-783. doi: 10.1136/ard.2009.108233 pmid: 19297344
[8]	Ramiro S, Stolwijk C, van Tubergen A, et al. Evolution of radiographic damage in ankylosing spondylitis: A 12 year prospective follow-up of the OASIS study[J]. Ann Rheum Dis, 2015, 74(1) : 52-59. doi: 10.1136/annrheumdis-2013-204055 pmid: 23956249
[9]	Landewé R, Dougados M, Mielants H, et al. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine[J]. Ann Rheum Dis, 2009, 68(6):863-867. doi: 10.1136/ard.2008.091793 pmid: 18628283
[10]	Ahidfar S, Sunar I, Ataman ş, et al. Ultrasonographic evaluation of achilles tendon: Is there any difference between ankylosing spondylitis, non-radiographic axial spondyloarthropathy and controls?[J]. Int J Rheum Dis, 2020, 23(4):511-519. doi: 10.1111/1756-185X.13796 pmid: 31985181
[11]	Kwan YH, Tan JJ, Phang JK, et al. Validity and reliability of the ankylosing spondylitis disease activity score with C-reactive protein (ASDAS-CRP) and bath ankylosing spondylitis disease activity index (BASDAI) in patients with axial spondyloarthritis (axSpA) in Singapore[J]. Int J Rheum Dis, 2019, 22(12):2206-2212. doi: 10.1111/1756-185X.13735 pmid: 31721427
[12]	Solmaz D, Uslu S, Kozacı D, et al. Evaluation of periostin and factors associated with new bone formation in ankylosing spondylitis: Periostin may be associated with the Wnt pathway[J]. Int J Rheum Dis, 2018, 21(2):502-509. doi: 10.1111/1756-185X.13186 pmid: 28941122
[13]	van Tubergen A, van der Heijde D, Dougados M, et al. Are syndesmophytes most prevalent in the lumbar or in the cervical spine in patients with ankylosing spondylitis and do they develop in a specific direction[J]? Rheumatology (Oxford), 2012, 51(8):1432-1439. doi: 10.1093/rheumatology/kes052 pmid: 22467083
[14]	van Tubergen A, Ramiro S, van der Heijde D, et al. Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: A longitudinal study[J]. Ann Rheum Dis, 2012, 71(4): 518-523. doi: 10.1136/annrheumdis-2011-200411 pmid: 21989544
[15]	Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis[J]. Arthritis Rheum, 2012, 64(5):1388-1398.
[16]	Kang KY, Kwok SK, Ju JH, et al. The predictors of development of new syndesmophytes in female patients with ankylosing spondylitis[J]. Scand J Rheumatol, 2015, 44(2): 125-128. doi: 10.3109/03009742.2014.938693 pmid: 25352247
[17]	Baraliakos X, Van den Bosch F, Machado PM, et al. Achievement of remission endpoints with secukinumab over 3 years in active ankylosing spondylitis: Pooled analysis of two phase 3 studies[J]. Rheumatol Ther, 2021, 8(1): 273-288. doi: 10.1007/s40744-020-00269-6 pmid: 33351179
[18]	Webers C, Stolwijk C, Schiepers O, et al. Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: An ancillary study to a randomized controlled trial[J]. Arthritis Res Ther, 2020, 22(1): 225-231.
[19]	Enginar AÜ, Daltaban Ö, Kaçar C, et al. Relationship between periodontal status and disease activity in patients with ankylosing spondylitis[J]. Reumatologia, 2021, 59(1):35-40.
[20]	Zhao D, He D, Bi L, et al. Safety and efficacy of prefilled liquid etanercept-biosimilar yisaipu for active ankylosing spondylitis: A multi-center phase III trial[J]. Rheumatol Ther, 2021, 8(1):361-374. doi: 10.1007/s40744-021-00276-1 pmid: 33559842
[21]	Anja W, Kirsten M, Joachim L, et al. Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC[J]. RMD Open, 2017, 3(1):366-371. doi: 10.1136/rmdopen-2016-000366 pmid: 28405472
[22]	Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-Year longitudinal data from the OASIS cohort[J]. Ann Rheum Dis, 2014, 73(8) : 1455-1461. doi: 10.1136/annrheumdis-2014-205178 pmid: 24812292
[23]	Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis[J]. Arthritis Rheum, 2013, 65(10) : 2645-2654.
[24]	Poddubnyy D, Sieper J. Mechanism of new bone formation in axial spondyloarthritis[J]. Curr Rheumatol Rep, 2017, 19(9):55-61. doi: 10.1007/s11926-017-0681-5 pmid: 28752489
[25]	Song IH, Hermann KG, Haibel H, et al. Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body M in early axial spondyloarthritis-3-Year data of the ESTHER triall[J]. Semin Arthritis Rhe RIum, 2016, 45(4):404-410.
[26]	Poddubnyy D, Listing J, Sieper J. Brief report: Course of active inflammatory and fatty lesions in patients with early axial spondyloarthritis treated with infliximab plus naproxen as compared to naproxen alone: Results from the infliximab as first line therapy in patients with early active axial spondyloarthritis trial[J]. Arthritis Rheumatol, 2016, 68(8):1899-1903.
[27]	Zhao SS, Solomon DH, Goodson NJ. Comment on: Comorbidity burden in axial spondyloarthritis: A cluster analysis: Reply[J]. Rheumatology (Oxford), 2020, 59(3):692-693. doi: 10.1093/rheumatology/kez573 pmid: 31865393
[28]	Feldtkeller E, Khan MA, van der Heijde D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs positive patients with ankylosing spondylitis[J]. Rheumatol Int, 2003, 23(2):61-66. doi: 10.1007/s00296-002-0237-4 pmid: 12634937